Oct 20, 2026
OpenAI acquires Orchestra Bio and brings its team and drug-development coordination platform into Rosalind, its life-sciences models and tools.
Connects scientific AI with the work of tracking studies, manufacturing dependencies and development decisions. The announcement describes an acquisition and research workflow ambitions, not an approved treatment.